Adrian Bebenek
@AdrianBebenek
Followers
407
Following
330
Media
5
Statuses
385
Fellow @Vida_Ventures || @Harvard Chem Bio PhD Candidate @SchreiberStuart @TheXavierLab Labs || @Yale B.S. @CraigMCrews Lab || 🇵🇱
Joined April 2013
RT @CellChemBiol: Development of an FKBP12-recruiting chemical-induced proximity DNA-encoded library and its application to discover an aut….
0
9
0
RT @AppleHelix: I think this will become much more common going forward. Pharma in-licensing IND-enabled or Phase 1 assets. Frankly, this….
0
2
0
RT @TheXavierLab: New work out now @CellChemBiol! We developed a non-degrader CIP-DEL platform for discovery of modulators of protein-prote….
0
6
0
RT @TheXavierLab: (1/5) Excited to share this collab with the Cravatt lab at @scrippsresearch! A structurally diverse library of photoreact….
0
5
0
RT @Vida_Ventures: #CandidTherapeutics, led by Ken Song, launched today with $370M in funding. Vida is proud to support Candid as it develo….
0
1
0
RT @realJimWells: Big day for the lab as our MultiMap platform is now published on Science! Congratulations to Lindsey @Zhi_Lindsey_Lin and….
0
15
0
RT @fperrywilson: Well we finally got an Ozempic vs. Mounjaro head-to-head (kind of). Brief thread to break down the weight-loss-drug sh….
0
122
0
RT @adamfeuerstein: $LLY buyinng $MORF $3.2B - oral integrin for inflammatory bowel disease. $57 per share. 78% premium. .
0
17
0
RT @XWang829: Previous papers have shown that drug targets with supporting genetic evidence can have twice the success rate when reaching c….
0
26
0
RT @JorgeCondeBio: Recent draft guidance from @US_FDA on 'platform technology designation' would enable companies to reuse prior data for f….
0
40
0
RT @Pharmdca: $VKTX . Infact $AMGN discontinuing Oral drug either due to low efficacy or Safety issues is big positive for $VKTX . $AMGN Re….
0
8
0
RT @ptimshel: Does single-cell data increase probability of success in drug discovery and clinical success? 🧐.Drug targets backed by single….
0
21
0
RT @RapeLab: Congratulations to #MolecularTherapeutics faculty @bignerdzzy and @kevansf on their wonderful paper on targeting the G12D vari….
0
17
0
RT @PharmDabbler: $VKTX obesity market has all the momentum. Likely suitors: .- $PFE - just pulled their Ph3 trial from Danuglipron twice….
0
8
0
RT @bloodgenes: Wonderful to have our paper, "Inherited blood cancer predisposition through altered transcription elongation", published (o….
0
72
0
Congratulations @SchreiberStuart! I am very excited to see all that comes out of @arenabioworks — a new model for drug discovery is desperately needed! .
0
1
6
RT @DanNomura: Congrats to our chem bio grad student Margot Meyers @MeyersM037 on her ACS Chem Bio paper on the discovery of a covalent DD….
0
11
0
Congrats to @_chrisgparker_ and team on the dev of a covalent (PPI) inhibitor of SLC15A4 — highlighting the power of chemoproteomics for IDing modulators of difficult membrane targets. Love all the attn to I&I this last year
1
1
23
RT @doctorveera: GWAS and ExWAS of human hypothalamus volumes identify a strong association with ADAMTS8 (encodes an angiogenesis-inhibitin….
0
10
0
RT @pottslab: CAND1 is a conditional inhibitor for CRL2 E3s dependent on CRL2 substrate Kd. Unlike CRL1 E3s that have fast on rates, CRL2 E….
0
5
0